Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Small Cell Lung Carcinoma 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

pegfilgrastim 26Filgrastim 24Cyclophosphamide 8Docetaxel 7Etoposide 6pegylated granulocyte colony-stimulating factor 5Cytarabine 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Leucovorin 3Fluorouracil 3Doxorubicin 3Cyclosporine 3Cefepime 3Caspofungin 3Carboplatin 3liposomal amphotericin B 2Vincristine 2Vancomycin 2Topotecan 2Methylprednisolone 2Methotrexate 2Itraconazole 2Irinotecan 2Ifosfamide 2Idarubicin 2Fluconazole 2Daunorubicin 2Cisplatin 2Amikacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neutropenia × EC regimen × Clear all
NCT02527746 2024-02-23

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

EVIVE Biotechnology

Phase 1 Completed
18 enrolled 22 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡